Trial Profile

A Phase I, Open Label Study Employing the Topical Immunomodulator Diphencyprone to Treat Cutaneous Neurofibromas Associated With NF1

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diphencyprone (Primary)
Indications Neurofibroma; Neurofibromatosis 1; Skin cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

02 May 2024 Status changed from active, no longer recruiting to completed.
12 Mar 2024 Results (n=12) assessing the safety, tolerability, and efficacy of DPCP for the treatment of CNs presented at the American Academy of Dermatology annual Meeting 2024
03 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com